A recent article in The Incidental Economist examines new approaches to paying for high-cost gene therapies, focusing on “rev pay” models that spread payments over time rather than requiring a large...
A new STAT article highlights major shifts in CVD prevention guidelines, including considering statins as early as age 30 and using updated risk tools. CP3’s Dr. Tim Anderson, interviewed for the...
A new CIDRAP article examines practical strategies to curb inappropriate antibiotic prescribing in dental care, a persistent contributor to antimicrobial resistance and avoidable patient harm. The...
A new CIDRAP report highlights that dentists continue to prescribe millions of antibiotics each year in the U.S., often for prophylaxis or conditions where they may not be indicated, raising ongoing...
A major Lancet meta-analysis reported that most side effects commonly attributed to statins are not supported by strong evidence, with only a few rare risks confirmed and the cardiovascular...
In a recent Pitt Med feature, CP3’s Dr. Tom Radomski reflects on his journey from student to Associate Director of the Institute for Clinical Research Education (ICRE) at the University of Pittsburgh...
CP3 Director Dr. Walid Gellad will moderate a panel titled “Focus on Non-Government Payers” at the upcoming conference Novel Solutions to Address the Rising Cost of Oncology Drugs: Targeting the...
Two CP3 faculty affiliates, Dr. Sarah Belcher and Dr. Luke Berenbrok, were recently highlighted in the Pitt Research Annual Report for work that advances medication use and patient care. Dr. Belcher’s...
We are excited to start the year by planning to share our risk prediction work at two upcoming conferences the UPMC Digital Health Summit and theCollege on Problems of Drug Dependence's (CPDD)...
CP3’s own Dr. Tim Anderson was interviewed for a New York Times story examining recent trends in the use of GLP-1 weight-loss medications among older adults and the factors driving changes in patient...
